SCHEMBL7520399

SCHEMBL7520399

NC(CCC(=O)O)(CCC(=O)O)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
THRB P10828 3/20 0.52
CYP1A2 P05177 2/20 0.52
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 2/20 0.52
LMNA P02545 7/20 0.47
EGLN1 Q9GZT9 2/20 0.47
ALKBH5 Q6P6C2 1/20 0.47
SUCNR1 Q9BXA5 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.42
TSHR P16473 3/20 0.41
GABRR1 P24046 2/20 0.41
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
BLM P54132 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GABRR3 A8MPY1 1/20 0.41
GABRP O00591 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28384994 0.97 KMT2A (0.50) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL10629764 0.87 LMNA (0.56) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL21983371 0.87 LMNA (0.52) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL3838466 0.86 THRB (0.46) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL10338097 0.84 ALDH1A1 (0.45) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL28164678 0.84 ALDH1A1 (0.61) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL21118980 0.83 CYP1A2 (0.41) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL22422223 0.83 CYP1A2 (0.41) KMT2ATHRBCYP1A2MEN1ALDH1A1
SCHEMBL2029796 0.81
SCHEMBL123829 0.81 KMT2A (0.52) KMT2ATHRBCYP1A2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661892-A1 TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME Navigen, Inc. (US) 2025-12-17 EP claimed
CN-119909235-A Medical lubricant and preparation method thereof 河北医科大学第一医院 2025-05-02 CN claimed
WO-2024168055-A1 TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME NAVIGEN, INC. (US) 2024-08-15 WO claimed
US-20230127824-A1 IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED RADIOPACITY BOSTON SCIENTIFIC SCIMED INC. (US) 2023-04-27 US claimed
CN-109069577-B D-peptide inhibitors of HIV entry and methods of use 纳维根公司 2022-08-19 CN claimed
EP-3399994-B1 D-PEPTIDE INHIBITORS OF HIV ENTRY AND METHODS OF USE NAVIGEN INC (US) 2020-09-16 EP claimed
US-20190023748-A1 D-PEPTIDE INHIBITORS OF HIV ENTRY AND METHODS OF USE THE UNIVERSITY OF UTAH 2019-01-24 US claimed
EP-3399994-A1 D-PEPTIDE INHIBITORS OF HIV ENTRY AND METHODS OF USE Navigen, Inc. (US) 2018-11-14 EP claimed
WO-2017120549-A1 D-PEPTIDE INHIBITORS OF HIV ENTRY AND METHODS OF USE NAVIGEN, INC. (US) 2017-07-13 WO claimed
EP-4737504-A2 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF Xiamen Sinopeg Biotech Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-4276090-B1 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF XIAMEN SINOPEG BIOTECH CO LTD (CN) 2026-04-29 EP disclosed
EP-4661892-A1 TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME Navigen, Inc. (US) 2025-12-17 EP disclosed
CN-119909235-A Medical lubricant and preparation method thereof 河北医科大学第一医院 2025-05-02 CN disclosed
WO-2025038709-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-02-20 WO disclosed
US-7888536-B2 Selective and specific preparation of discrete PEG compounds QUANTA BIODESIGN, LTD. (US) 2011-02-15 US disclosed
US-20080317668-A1 Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications BRACCO IMAGING S.P.A. (IT) 2008-12-25 US disclosed
US-20070053840-A1 Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents HEALTH RESEARCH, INC. (US) 2007-03-08 US disclosed
EP-0714903-B1 Carbohydrate conjugates as cell adhesion inhibitors GLYCOREX AB (SE) 2002-05-15 EP disclosed
US-5858994-A BIND TO SELECTIN RECEPTORS HOECHST AKTIENGESELLSCHAFT (DE) 1999-01-12 US disclosed
EP-0714903-A1 New carbohydrate conjugates as cell adhesion inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1996-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190023748-A1 D-PEPTIDE INHIBITORS OF HIV ENTRY AND METHODS OF USE DNPEP, ANPEP, CD4 KMT2A 4842/4885THRB 3010/4885CYP1A2 4883/4885
US-20070053840-A1 Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents VHL, HMBS, PPOX KMT2A 4466/4885THRB 1139/4885CYP1A2 4839/4885
US-20080317668-A1 Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications ITGA2B, ITGB2, ITGB1 KMT2A 3272/4885THRB 208/4885CYP1A2 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.